Managers / Q1 2025 · view latest →
MVM Partners, LLC
CIK 0001947083 · OLD CITY HALL, 45 SCHOOL STREET, BOSTON, MA, 02108 · 617-383-2101
Summary
Mvm Partners, LLC reported $79M in U.S.-listed holdings across 3 positions for Q1 2025.
The portfolio is heavily concentrated: Paragon 28 alone accounts for 80.4% of reported value.
The book was largely unchanged from Q4 2024.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 91.7% · $72M
- Other · 8.3% · $7M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2024 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| Paragon 28 Inc | TRIMMED | −5.53M | 4.85M | −$44M | $63M |
| MDXHealth SA | HELD | +0 | 4.70M | −$4M | $7M |
| Optinose Inc | HELD | +0 | 973.7K | +$3M | $9M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2025
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | Paragon 28 Inc | COM | 80.36% | $63M | 4.85M |
| 2 | Optinose Inc | COM New | 11.30% | $9M | 973.7K |
| 3 | MDXHealth SA | SHS New | 8.34% | $7M | 4.70M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $11M | 1 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $17M | 1 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $22M | 1 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $10M | 1 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $79M | 3 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $124M | 3 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $92M | 3 | Nov 1, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $100M | 3 | Jul 25, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $167M | 3 | May 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $172M | 3 | Feb 12, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $294M | 3 | Feb 13, 2023 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.